ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'

(University of Colorado Denver) Promising clinical trial results presented at the American Society for Clinical Oncology Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
Source: EurekAlert! - Biology - Category: Biology Source Type: news